Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Subscribe To Our Newsletter & Stay Updated